Recursion registers Phase 1/2 trial of REC-7735 in PIK3CA-H1047R solid tumors
Recursion Pharmaceuticals listed a new Phase 1/2 study testing REC-7735 in patients with PIK3CA-H1047R mutated solid tumors, with recruitment underway at one of three planned US sites.
Recursion's registry activity for the week centers on one newly listed early-phase oncology trial.
- REC-7735, an oral drug, is being tested in a Phase 1/2 study for unresectable, locally advanced, or metastatic PIK3CA-H1047R mutated solid tumors, with the study assessing safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity.1 The study, sponsored by Recursion Pharmaceuticals Inc., is recruiting and plans to enroll 90 participants1 across three US sites, though only START Midwest in Grand Rapids, Michigan is recruiting, while NEXT Oncology - Dallas and NEXT Virginia are not yet recruiting.1 Primary outcomes include dose-limiting toxicities in Phase 1A and, in Phase 1B, objective response rate according to RECIST 1.1.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.